Syros Pharmaceuticals investor relations material

Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. With its proprietary platform technology, Syros is developing an innovative pipeline of small molecule drugs designed to act at the level of the genome to promote cell survival, block disease activity and restore healthy homeostasis in patients.The company have indentified several drug targets in cancer and metabolic diseases, including disease-causing genes methyltransferases and histone acetyltransferases (HATs), as well as drivers of master oncogenic pathways such as PI3K and MEK.